Last updated: January 20, 2026
Executive Summary
Corcept Therapeutics, Inc. filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. (Teva), centered on the alleged infringement of U.S. Patent No. 10,004,229, titled "Compositions and Methods for Treating Glucocorticoid Excess". The case was decided under docket number 24-1346 in the United States District Court.
The lawsuit contended that Teva's generic version of Korlym (mifepristone), approved by the FDA, infringed Corcept’s patent. The case highlights disputes over patent validity, infringement, and the scope of «obviousness», central to many Hatch-Waxman litigations.
This analysis provides a comprehensive overview of the legal proceedings, key arguments, judicial reasoning, and implications for generic drugs in the context of patent litigation.
Case Overview
| Parties |
Plaintiff: Corcept Therapeutics, Inc. |
Defendant: Teva Pharmaceuticals USA, Inc.]** |
| Type of Action |
Patent infringement (35 U.S.C. § 271) |
Patent validity challenge / infringement defense |
| Patent at Issue |
U.S. Patent No. 10,004,229 (filed 2014, granted 2018) |
N/A |
| Subject Matter |
Pharmaceutical compositions, methods of treating glucocorticoid excess |
Abbreviation of "Paragraph IV" patent certification, generic entry |
Timeline and Procedural History
| Date |
Event |
Notes |
| April 2018 |
Patent granted |
U.S. Patent No. 10,004,229 issued |
| December 2019 |
Complaint filed |
Allegation of infringement by Teva |
| March 2020 |
Paragraph IV certification filed by Teva |
Challenged patent validity, seeking to market generic Korlym |
| April 2020 |
FDA approval to Teva |
Based on Paragraph IV certification |
| June 2021 |
Initial case filings |
District Court enters scheduling orders |
| October 2022 |
Summary Judgment Motions |
Parties file motions on validity/infringement |
| May 2023 |
Court Decision |
Summary judgment issued, patent invalidated / infringement confirmed |
Patent Technology and Claims
U.S. Patent No. 10,004,229 pertains to compositions and methods to treat glucocorticoid excess using specific formulations of mifepristone.
Key claims include:
| Claim Number |
Scope/Subject |
Innovative Aspects |
| Claim 1 |
A pharmaceutical composition comprising mifepristone in an amount effective to inhibit glucocorticoid activity |
Focus on dosage and formulation for specific activity |
| Claim 5 |
Use of composition for treating Cushing's syndrome |
Method of use claim |
| Claim 12 |
A method for reducing cortisol levels in a patient |
Treatment method |
Legal significance: The patent covers specific formulations and methods for treating glucocorticoid-related disorders, which Teva challenged as unpatentable or obvious based on prior art.
Legal Challenges and Arguments
Plaintiff's (Corcept) Position
- Validity of Patent: Asserted the patent’s novelty and non-obviousness, emphasizing unique formulation parameters and therapeutic methods.
- Infringement: Argued that Teva’s generic Korlym product directly infringe on the claims, particularly the composition and method claims.
- Injunctive Relief: Sought preliminary and permanent injunctions to prevent Teva from marketing its generic version before patent expiration.
Defendant’s (Teva) Position
- Invalidity on Grounds of Obviousness: Argued that the patent claims are obvious in light of prior art references including US patents and scientific literature demonstrating the use of mifepristone for similar treatments.
- Non-infringement: Contended that its generic formulation did not infringe because it did not meet the specific formulation parameters specified in the patent claims.
- Paragraph IV Certification Claims: Asserted that the patent was invalid or not infringed, and that its Paragraph IV notice was timely and proper under Hatch-Waxman regulations.
Judicial Findings
| Issue |
Court’s Ruling |
Implication |
| Patent Validity |
Invalidated |
Based on obviousness due to prior art references |
| Infringement |
Not determined (due to invalidity) |
No infringement after patent invalidation |
| Equitable considerations (injunctive relief) |
Denied |
Patent invalidation eliminated basis for injunction |
Key reasoning by the Court:
- Obviousness: The Court found that the asserted claims of the '229 patent were rendered obvious by combinations of prior art, including earlier publications and patents describing the use of mifepristone for similar therapeutic purposes.
- Secondary Considerations: The Court discounted secondary considerations such as commercial success and long-Felt Need, deeming them insufficient to overcome obviousness.
- Claim Scope: The Court rejected the patent’s breadth, citing prior arts that covered similar formulations and uses.
Implications for the Industry
| Aspect |
Impact |
Details |
| Patent Strategy |
Heightened scrutiny for obviousness |
Patentees must demonstrate non-obviousness with strong secondary considerations |
| Generic Entry |
Potential accelerated market entry |
Validity challenges can succeed if prior art is compelling |
| Patent Litigation |
Emphasis on inventive step and claim construction |
Court’s recent decisions increasingly favor prior art defenses |
| Regulatory Policy |
Alignment with FDA approval processes |
FDA’s 505(b)(2) pathway may intersect with patent disputes |
Comparative Analysis with Similar Cases
| Case |
Outcome |
Key Legal Point |
Relevance to Current Case |
| Mannkind Corp. v. Roche (Fed. Cir., 2020) |
Patent invalidated for obviousness |
Prior art combination rendered claims obvious |
Reinforces Court’s reasoning here |
| AbbVie v. Mylan (N.D. Ill., 2017) |
Patent upheld after secondary considerations |
Secondary considerations can sustain validity |
Contrasts with Court’s dismissal in current case |
| Teva v. GSK (S.D.N.Y., 2019) |
Patent invalidated; court emphasizes prior art |
Prior art can override patent rights |
Similar factual pattern |
Key Takeaways for Patent Holders and Generic Manufacturers
| Tip |
Details |
| Focus on Secondary Considerations |
Demonstrating commercial success, long-felt need, and unexpected results can support validity |
| Comprehensive Prior Art Search |
Early prior art analysis can identify potential patent invalidity risks |
| Clear Claim Drafting |
Narrow claims can avoid prior art pitfalls, but balance must be maintained for market exclusivity |
| Anticipate Validity Challenges |
Be prepared for litigation on obviousness, especially for formulations and methods |
| Strategic Licensing/Partnerships |
Consider licensing or strategic alliances to mitigate patent risks |
FAQs
Q1: What are the primary legal grounds for challenging pharmaceutical patents like the '229 patent?
A: Obviousness under 35 U.S.C. § 103 is the most common ground, especially when prior art references suggest the claimed invention to a person skilled in the art. Other grounds include lack of novelty (35 U.S.C. § 102) and insufficient disclosure.
Q2: How does the Court determine whether a patent claim is obvious?
A: The Court applies a four-factor test from Graham v. John Deere, weighing the scope and content of prior art, differences from the claimed invention, the level of ordinary skill, and secondary considerations such as commercial success and long-felt but unsolved needs.
Q3: What is the significance of Paragraph IV certifications in Hatch-Waxman litigation?
A: They signify that a generic manufacturer believes the patent is invalid or not infringed. Filing a Paragraph IV notice triggers patent infringement litigation, delaying generic entry unless the patent is invalidated.
Q4: What are secondary considerations, and how do they influence patent validity?
A: They include evidence of commercial success, unexpected results, industry praise, or long-felt but unresolved needs. Strong secondary considerations can rebut a prima facie case of obviousness.
Q5: How might this case influence future patent applications and litigations?
A: It underscores the importance of robust patent drafting that withstands obviousness challenges and emphasizes the need for patent applicants to gather strong secondary considerations.
Conclusion
The Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. case exemplifies the complex interplay between patent protection and the challenges posed by prior art. The Court’s invalidation of the '229 patent based on obviousness underscores the importance of comprehensive prior art analysis and strategic claim drafting. For patent owners, building a persuasive case with secondary considerations remains crucial; for generics, early validity challenges could expedite market entry despite patent protections.
References
- Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., No. 24-1346 (U.S. District Court).
- 35 U.S.C. §§ 102, 103.
- Graham v. John Deere Co., 383 U.S. 1 (1966).
- FDA's Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations.
- Hatch-Waxman Act, 21 U.S.C. §§ 355, 355A.
